FibroBiologics (FBLG) CEO adds 51,500 shares in open-market buys

Rhea-AI Filing Summary

FibroBiologics, Inc. chief executive officer Pete O'Heeron reported open-market purchases of 51,500 shares of common stock across three days. He bought 17,428 shares on March 2, 18,200 on March 3, and 15,872 on March 4, 2026, bringing his direct holdings to 5,958,147 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'HEERON PETE

(Last) (First) (Middle)

C/O FIBROBIOLOGICS, INC.

455 E. MEDICAL CENTER BLVD., SUITE 300

(Street)

HOUSTON TX 77598

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		P		17,428	A	$0.353(1)	5,924,075	D
Common Stock	03/03/2026		P		18,200	A	$0.4051(1)	5,942,275	D
Common Stock	03/04/2026		P		15,872	A	$0.3784(1)	5,958,147	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $0.3210 to $0.4166 on March 2, 2026, $0.3885 to $0.4302 on March 3, 2026, and $0.3730 to $0.3820 on March 4, 2026. The reporting person will provide upon request to the SEC, the Issuer, or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

	/s/ Ruben A. Garcia, by Power of Attorney	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did FibroBiologics (FBLG) report in this Form 4 filing?

FibroBiologics reported that CEO Pete O'Heeron purchased 51,500 shares of common stock in open-market transactions over three days in March 2026. These buys increased his directly held stake to 5,958,147 shares according to the amounts disclosed in the filing.

How many FibroBiologics (FBLG) shares did the CEO buy and on which dates?

The CEO bought 17,428 shares on March 2, 18,200 shares on March 3, and 15,872 shares on March 4, 2026. All transactions involved FibroBiologics common stock and were reported as open-market purchases under transaction code "P" in the Form 4.

What prices were paid in the FibroBiologics (FBLG) CEO share purchases?

The Form 4 lists weighted average prices of $0.3530, $0.4051, and $0.3784 for the three purchase dates. A footnote explains the actual trades occurred in multiple transactions ranging from $0.3210 to $0.4302 over March 2–4, 2026.

What is Pete O'Heeron’s FibroBiologics (FBLG) ownership after these transactions?

After the reported open-market purchases, Pete O'Heeron directly owns 5,958,147 shares of FibroBiologics common stock. The Form 4 indicates these shares are held with direct ownership, categorized with the ownership code "D" for the reporting person.

Were the FibroBiologics (FBLG) CEO transactions buys or sells?

All reported transactions were buys. Each entry is coded "P" for purchase and described as an open-market purchase, with the transaction direction flagged as "buy" and no sales or dispositions reported in this Form 4 filing.